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 ABSTRACT 
 
Objective: The objective of this review is to determine whether ivabradine therapy can 
improve the quality of life in cardiovascular disease patients. 
 
Study Design: The studies included in this review are one randomized control study and 
two double blind randomized control studies from 2008, 2010, and 2012. 
 
Data Source: The three studies in this review were obtained by performing a PubMed 
search using the keywords “ivabradine” and random control trial.” All articles were 
published in English and in peer-reviewed journals.  
 
Outcomes Measured: The three studies ascertained whether there was a decrease in 
hospitalization events within coronary artery disease and heart failure patients, if there 
was a subjective increase in the quality of life in heart failure patients, and whether there 
was an improvement in NYHA heart failure classification after ivabradine treatment. 
 
Results: Patients with a resting heart rate of 70 beats per minute or greater who were 
treated with ivabradine demonstrated a statistically significant reduction in hospital 
admissions for myocardial infarctions (HR=0.64; 95% CI 0.49–0.84; p=0.001). This is a 
36% reduction in myocardial infarctions. Heart failure patients treated with ivabradine 
were found to have a significantly lower risk of suffering a hospitalization event for 
worsening heart failure than the placebo group (HR=0.75; 95% CI 0.65-0.87; p<0.001). 
Also, patients receiving ivabradine were statistically less likely to become hospitalized a 
second time as compared to the placebo group (HR=0.66; 95% CI 0.55-0.79; p<0.001). 
After three months of treatment with ivabradine, there was a significant decline in the 
NYHA functional class of heart failure within the ivabradine treatment group (p<0.0001), 
and a significant improvement in the quality of life scores within the ivabradine treated 
group (p<0.0001). 
 
Conclusions: Based on the systematic reviews of the three randomized controlled trials, 
one can conclusively say that Corlanor (ivabradine) can improve the quality of life in 
cardiovascular disease patients. All three studies demonstrated statistically significant 
changes compared to control/placebo groups. These studies also demonstrate that 
ivabradine is efficacious and is well tolerated in terms of being safe for human use. 
 
Key Words: Ivabradine, Heart Failure, Coronary Artery Disease, Quality of Life, NHYA.
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INTRODUCTION 
Heart failure (HF) is the end result from many etiological factors that should be 
considered a clinical syndrome and should not be considered a single entity.1 One of the most 
common causes of HF is coronary artery disease (CAD).1 Other risks and causes of HF are 
dyslipidemia, obesity, type 1 and 2 diabetes, hypertension, arrhythmias, cardiomyopathy, 
congenital heart defects, and heart valve diseases.1 Also cigarette smoking, alcohol abuse, drug 
abuse, hyperthyroidism, hypothyroidism, vitamin E intoxication, radiation to the thorax, and 
chemotherapy can contribute to HF.1 The end result of these complex interactions is the loss of 
functioning of the cardiac myocytes and/or an abnormality of cardiac muscle contraction, 
relaxation, or both.2 
 HF is relevant to both patients and practitioners for many reasons because it is a very 
common condition with approximately 5.1 million patients in the U.S. with a greater occurrence 
in men than in women, and an increasing prevalence with increasing age.3-4 Also, within the 
U.S., the incidence of HF is estimated to be 2-5 per 1,000 person-years.4 CAD, as the leading 
cause of HF, is the number one cause of death in both men and women where each year 
approximately 370,000-375,000 men and women die as a result.5 
 HF costs the U.S. an estimated $32 billion each year.6 This large number includes cost of 
health services, medications, and missed days of work.6 Secondly, the most common cause of 
HF, CAD, costs the U.S. an estimated $108.9 billion every year, which also includes the cost of 
health services, medications to treat, and lost time of productivity.7 Most of the cost arising from 
HF is from hospitalization events where 80% of hospitalizations are found to be within the aging 
U.S. Medicare population.4,8-9 Therefore, the rates of hospitalization and cost are expected to 
continually rise in the future with the increasing age of the U.S. population.9 There were over 1 
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million hospitalizations for HF in 2000 and in 2010.10 Interestingly, during this same time 
period, hospitalization rates for CAD declined by 43% for the total U.S. population.11  
There is a high risk of HF worsening or having an acute symptomatic attack, and there 
has been a reported high readmission rate to hospitals after newly diagnosed HF.12 Within the 
U.S. Medicare population, where HF is the most common reason for readmission to a hospital, a 
study showed that 27% of patients become readmitted within a 30-day period.12 There have also 
been high rates of re-admission after HF diagnosis reported in Canada.13 It has also been reported 
that patients with preserved left ventricular ejection fraction (LVEF) have re-admission rates as 
high as 29% after 60-90 days of leaving the hospital with a first incidence of HF.14 
In HF, it is medically recognized that the heart muscle cannot pump blood adequately to 
the bodily tissues because the muscle becomes too weak or too stiff to fill the heart chambers.2 
The most common cause of HF is from systolic dysfunction, which most commonly arises from 
myocardial infarcts related to CAD.1,2,5 The causes of CAD arise from smoking, high levels of 
cholesterol in the bloodstream, high blood pressure, insulin resistance or diabetes, and blood 
vessel inflammation.1,2,5 
 Symptoms of CAD can include dysrhythmias, chest pain or discomfort, angina, 
discomfort in one or both arms, the back, neck, jaw, or in the epigastric region, shortness of 
breath, nausea, vomiting, light-headedness or syncope, cold sweats, sleep disturbances, and 
fatigue.1,5 Signs of HF include edema of the ankles, feet, legs, abdomen, and distension in the 
veins of the neck.5,15 
The most common way to classify HF is the New York Heart Association’s (NYHA) four 
functional classes. Class IV are patients that have symptoms at rest.15 Class III have symptoms 
with less-than-ordinary types of exertion.15 Class II have symptoms with ordinary exertion, and 
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Class I patients have no symptoms attributable to heart disease or HF.15 NYHA class is also 
utilized to determine the prognosis of HF with increasing morbidity and mortality rates being 
directly proportional to increasing class scores.15  
The treatment of HF is multifaceted. In those with systolic HF, the main goal of treatment 
is to reduce symptoms, prolong survival, improve quality of life, and prevent disease 
progression.16 For those who have a structural issues of the heart, the therapy depends on the 
NYHA classification.16 For those that are Class I and asymptomatic, the goal is to deter any 
cardiac remodeling.16 For those that have symptoms (Classes II to IV), the goal is to deter fluid 
retention, decrease disability, and deter the progression of disease.16 Standard therapy for 
patients with HF who have a decreased LVEF should consist of angiotensin-converting enzyme 
inhibitor (ACEi) and a beta-blocker (BB).16 Other and additional therapy must be considered if a 
patient has persistent symptoms.16 These include angiotensin receptor blockers (NYHA Classes 
II to IV), spironolactone (NYHA Classes III and IV), a combination of hydralazine and 
isosorbide dinitrate (NYHA Classes III and IV), and eventually digitalis.16 Lastly, implantation 
of internal cardiac defibrillator, cardiac resynchronization, and heart transplants are down-the-
line choices of treatment.16 If HF is from CAD, then revascularization of the coronary vessels 
may be performed.16 
 Importantly, it has been noted that resting heart rate (HR) is related to mortality both 
within the general population without heart disease and in patients with myocardial infarcts or 
HF.17 It is also reported that heart related death is increased by 14% with an increase of 10 beats 
per minute (bpm) in HR, and that this increase is independent of age, exercise, blood pressure, 
and BMI.18-19 
 Thereby, it seems that resting HR can be considered a modifiable cardiovascular disease 
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risk factor in both the general population and in patients with HF and CAD. Ivabradine is a heart 
rate-lowering agent that is selective for and a specific inhibitor of the sinus node. It inhibits the If 
channel of the cardiac pacemaker.20-21 It reduces diastolic depolarization rates set forth by the 
sinoarterial node, therefore purely decreasing HR.20-21 Compared to BBs, which also lower HR, 
ivabradine does not lower blood pressure and may also reduce mortality and cardiac events 
independently or in conjunction with BBs.22  
OBJECTIVE 
 The objective of this systematic review is to determine whether or not ivabradine therapy 
can improve quality of life in cardiovascular disease patients? 
METHODS 
The studies included in this review are one randomized control study and two double 
blind randomized control studies.22-24 These studies were included since they did not 
discriminate between biological sex or ethnicity, patients had to be diagnosed with HF or CAD, 
utilized the same dosing of the intervening medication (ivabradine 2.5, 5.0, and 7.5mg), and 
compared the ivabradine treatment group to the control group.22-24 These studies also included a 
wide range of age to test whether this intervention can be applied to a variety of age groups, but 
all patients had to be at least the age of 18.22-24 Also, for a study to be considered for inclusion, it 
must have included over 50 persons within the study to achieve the power to detect a possible 
statistical significance, and must have utilized similar statistical methods for fair comparisons 
between studies. All articles were published in English within peer-reviewed journals and were 
investigated by the author for inclusion in this review. Keywords for the PubMed search were 
“ivabradine,” and “randomized control trial,” without any time restriction for how long ago the 
studies were published. The summary statistics utilized across the three studies were hazard ratio 
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(HR), p-values, control group event rate (CER), and experimental group event rate (EER), 
numbers needed to treat (NNT), relative benefit increase (RBI), absolute benefit increase (ABI), 
numbers needed to harm (NNH), relative risk increase (RRI), absolute risk increase (ARI). Table 
1 summarizes the demographics and characteristics of the inclusion and exclusion criteria from 
each study.    
Table 1: Demographics & Characteristics of Included Studies 
Study Type #  of 
Patients 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
Withdrawal Intervention
s 
Fox et 
al, 
200822 
Double 
blind 
RCT 
10,917 ≥ 18 
years 
old if 
diabet
ic or 
> 55. 
MI, 
revascularisati
on, LV 
ejection 
fraction of less 
than 40%. 
Sinus rhythm, 
resting heart 
rate of 60 bpm 
or greater. 
Angina stable 
for 3 months. 
Medication at 
stable doses 
for 1 month 
MI or 
revascularisatio
n within 
previous 6 
months; stroke 
or TIA within 
previous 3 
months; 
pacemaker, 
defibrillator; 
valvular 
disease; 
arrhythmias,unc
ontrolled 
hypertension; 
NYHA 
Class IV. 
Excluded 
patients 
receiving strong 
CYP3A4 
inhibitors 
220 Ivabradine 
5mg PO 
BID, can be 
increased to 
7.5mg BID 
or 2.5 BID 
depending 
on tolerance 
Borer 
et al, 
201223 
Double 
blind 
RCT 
6,505 ≥ 18 
years 
old 
Symptomatic 
chronic HF of 
≥4-week 
duration + left 
ventricular EF 
of ≤35%, 
hospitalized 
for worsening 
HF within 12 
months, in 
sinus rhythm 
and heart rate 
of ≥70 b.p.m. 
Those who 
are opposite 
of inclusion 
criteria, or 
non-
compliant 
131 Ivabradine 
5mg PO 
BID, can be 
increased to 
7.5mg BID 
or 2.5 BID 
depending 
on tolerance 
Sarullo 
et al, 
201024 
Single 
blind 
RCT 
60 Mean 
52.7 
+/- 
5.3 
Left 
ventricular 
ejection 
fraction 
UA, recent MI, 
decompensated 
CHF, valvular 
heart disease, 
AFib, 
0 Ivabradine 
5mg PO 
BID, can be 
increased to 
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yrs. (LVEF) 
<40%, 
NYHA 
classes II to 
III, sinus 
rhythm with 
heart rate at 
rest >70 
bpm 
uncontrolled 
arrhythmias, 
chronic 
pulmonary 
illness, renal 
insufficiency, 
abnormal 
exercise stress 
test, and 
neurological or 
orthopedic 
limitations. 
7.5mg BID 
if HR is 
>70bpm 
after 
treatment 
began 
 
OUTCOMES MEASURED 
 The outcomes measured encompassing the three studies were a decrease in 
hospitalization events (a proxy for increased quality of life), a subjectively measured increase in 
quality of life via a questionnaire, and whether there was an improvement in NYHA HF 
classification.22-24 Fox et al22 endpoint goal was to determine whether the rates of admission to 
the hospital for fatal and non-fatal acute myocardial infarction decreased with ivabradine 
treatment in a subgroup of patients that had resting heart rates >70 bpm.22 This was ascertained 
by collecting data from interviews performed at 2 weeks, 1 month, 3 months, 6 months, and 
every 6 months till the study ended.22 These author’s also tested if there was a difference 
between all causes of serious adverse events between the groups. 22   
 Borer et al23 was interested in whether the treatment with ivabradine had any effect upon 
the rate of hospitalizations between the treatment group and the placebo group of HF patients. To 
ascertain this, hospitalization events were tracked via hospital records.23 Based on the data 
available from Borer et al,23 the determination of the number of patients needed to treat to 
decrease another hospitalization event was calculated.  
 Sarullo et al24 tested whether there was a difference between NYHA functional class of 
HF after a three month period of treatment.24 The functional class of HF was measured both in 
the treatment group and within the control group.24 The author’s also measured whether 
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treatment with ivabradine influenced the quality of life (QOL) in their patients.24 QOL was 
ascertained by the application of the Minnesota Living with Heart Failure Questionnaire.25 It is a 
validated, widely used, self-administered questionnaire composed of 21 items focused on the 
effects of HF upon a patient’s physical, psychological, and socioeconomic level.26-27 These 
studies have shown it to be sensitive to the changes in QOL within HF patients.26-27 
RESULTS 
In the study conducted by Fox et al,22 there were no statistically significant differences 
between baseline characteristics. The utilization of cardiac medications was high between all 
patients, where 94% patients were receiving an aspirin or anticoagulant, 74% were on statins, 
90% were prescribed an ACEi or an angiotensin II receptor blocker, and 87% of all patients were 
receiving BBs.22 When the author’s included all study participants in their analysis, there was no 
statistical difference in the safety of treatment demonstrated between the two groups.22 There 
were 1,233 (22.5%) patients that experienced serious adverse events in the ivabradine group and 
1,239 (22.8%) in the placebo group (p=0.70). With this event rate, the calculated NNH, which is 
the number of patients who need to be treated to have a person incur a serious adverse event, was 
calculated to be -333 (Table 2). Meaning, for every 333 patients treated with ivabradine rather 
than placebo there will be one less patient with a serious adverse event. 
Table 2: Number Needed to Harm to avoid all serious adverse events  
Study CER EER RRI ARI NNH 
Fox et al 0.228 0.225 -0.013 -0.003 -333 
 
The authors’ performed a subgroup analysis of patients with a resting heart rate of 70 
bpm or greater.22 This group was composed of 463 (17%) patients in the ivabradine group and 
498 (19%) patients in the placebo group who reached the primary endpoint of the study.22 Within 
this subset of patients, there was a statistically significant reduction in the rates of hospital 
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admission for both fatal and non-fatal acute myocardial infarctions (HR=0.64; 95% CI 0.49–
0.84; p=0.001).22 This is a 36% reduction in myocardial infarction for patients on ivabradine 
whose heart rate is >70 bpm compared to placebo (Table 3).22 
In the study performed by Borer et al,23 the results in baseline characteristics for patients 
with HF had statistically significant differences between the treatment and placebo groups. 
Patients were significantly older in the treatment group (p=0.007), and the placebo group were 
more likely to be smokers (p=0.023).23 Heart rate was significantly greater within the placebo 
group compared to the treatment group (p=0.024).23 The placebo group were more likely to have 
suffered a stroke (p=0.033), to have been diagnosed with CAD (p=0.021), and were more likely 
to be on diuretics (p=0.034).23 There was no statistical differences between the two groups in 
gender, BMI, blood pressure, NYHA function classes, estimated glomerular filtration rate, 
duration of heart failure, causes of HF (ischemia, hypertension, diabetes, atrial fibrillation), and 
in the many types of treatment regimens.23   
Comparing the groups after two years of follow-up, the study demonstrated that patients 
treated with ivabradine were significantly at a lower risk of suffering a hospitalization event for 
worsening HF than were patients receiving the placebo (HR=0.75; 95% CI 0.65-0.87; 
p<0.001)(Table 3).23 In terms of suffering a secondary hospitalization event, patients receiving 
ivabradine were statistically less likely to become hospitalized a second time as compared to the 
placebo group (HR=0.66; 95% CI 0.55-0.79; p<0.001) (Table 3).23 
Table 3: Statistical Significance of Treatment Endpoints  
Study Prevention Endpoint Hazard Ratio 
95% Confidence 
Interval P-value 
Fox et al22 Admission to hospital for myocardial infarction 0.64 0.49-0.84 0.001 
Borer et al23 First hospitalization event from HF 0.75 0.65-0.87 <0.001 
Borer et al23 Second hospitalization event from HF 0.66 0.55-0.79 <0.001 
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Sixteen percent of patients treated with ivabradine suffered a hospitalization event 
compared to 21% of from the placebo group (Table 4).23 After calculating the NNT, for every 20 
patients treated with ivabradine there was one fewer hospitalization event due to worsening HF. 
In terms of having a second hospitalization event, six percent of patients treated with ivabradine 
had two events compared to the placebo group that had nine percent of patients experiencing two 
hospitalizations (Table 4). These calculations show that the number of patients needed to treat 
with ivabradine to prevent one less first or second hospitalization event is 20 and 33, 
respectively.  
Table 4: NNT to reduce hospitalization events in HF patients (Borer et al 2012) 
Event CER EER RRR ARR NNT 
1st hospitalization event 0.21 0.16 -0.24 -0.05 -20 
2nd hospitalization event 0.09 0.06 -0.333 -0.03 -33 
 
As seen from the studies above, HF due to its progressive disease course can cause 
multiple exacerbations and hospitalizations leading to both high monetary costs and morbidity.6-
7,22-24 An important aspect in treating HF is to reduce disease progression and increase the quality 
of life within these patients. Sarrulo et al24 attempted to ascertain whether NYHA functional 
class of HF changed after ivabradine treatment, and whether QOL improved with ivabradine 
treatment. At baseline, there was no difference between the ivabradine treatment group and the 
control group in terms of NYHA functional class (ivabradine group 2.5±0.1 [mean and standard 
deviation] versus the control group 2.6±0.1).24 However, after three months of treatment, there 
was a statistically significant decline in the NYHA class within the ivabradine treatment group 
(1.6±0.1; p<0.0001).24 There was no such decline in NYHA class found within the control group 
(Table 5).24 At baseline, there was no statistical difference between the QOL life scores between 
the treatment and control group (ivabradine 30.9±2.3 versus controls 30.6±2.1).24 After three 
months of treatment, there was a significant improvement in QOL scores within the ivabradine 
Lynch, Ivabradine and Heart Failure 10 
group (37.5±1.9; p<0.0001), and there was no such significant improvement found within the 
control group.24 
Table 5: Mean and Standard Deviations between Groups (Sarullo et al 2010) 
Variable Ivabradine Group Control Group 
Baseline Post 3 Months Treatment Baseline Post 3 Months Treatment 
NYHA Class 2.5±0.1 1.6±0.1 (p<0.0001) 2.6±0.1 2.4±0.2 
Quality of Life 30.9±2.3 37.5±1.9 (p<0.0001) 30.6±2.1 31.2±2.6 
 
DISCUSSION 
 
With these statistical findings it should be noted that there were also findings where 
ivabradine treated groups did not differ from control groups. Fox et al reported22 no statistical 
difference between all-causes of death, cardiovascular death, and admission to the hospital for 
new-onset or worsening heart failure in all patients regardless of HR. Therefore, it is 
hypothesized that ivabradine may have specific criteria within the treatment of CAD and HF. 
  Ivabradine was approved by the European Medicines Agency in 2005 and the data 
described in this review comes from European research.22-24 Very recently, as of April 2015, the 
FDA approved the use of ivabradine under the brand name of Corlanor.28-29 It is indicated to 
reduce the risk of hospitalization in worsening HF patients that have stable, symptomatic chronic 
HF with LVEF ≤35%, who are in sinus rhythm with resting heart rate ≥70 bpm, and are either on 
maximally tolerated doses of BBs or have a contraindication to BB use.30 According to the 
manufacturer, Corlanor is contraindicated in patients with decompensated heart failure, a blood 
pressure less than 90/50 mmHg, in those with sick sinus syndrome, have a sinoatrial block or 3rd 
degree AV block, a resting heart rate of <60 bpm, severe hepatic impairment from any cause, 
have a pacemaker, and consume strong medications or foods that inhibit cytochrome P450 
3A4.30 Currently, wholesale costs for Corlanor is around $4,500 per year, or $375 per month, and 
patient costs vary according to insurance coverage.29  
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CONCLUSION 
  Based on the systematic reviews of the three randomized controlled trials, one can 
conclusively say that Corlanor (ivabradine) can improve the quality of life in cardiovascular 
disease patients. These three studies demonstrate that ivabradine treatment, by means of heart 
rate reduction, can significantly reduce the incidence of myocardial infarction in CAD, decrease 
hospitalization events in HF patients, decrease HF severity in terms of NYHA functional class, 
and increases HF patient’s perception of their QOL.22-24 These three studies demonstrate the 
utility, safety, and efficacy of ivabradine. These studies have some limitations as well, such as a 
fair amount bradycardia in the treatment group which may have resulted from the low average 
heart rate to begin with (all patients average = 71.9 bpm)22, one study was a post hoc analysis of 
a RCT where hospitalization rates may have been influenced by differing admission criteria 
between the health systems involved and between the different countries participating in the 
study23, and one study was a single-blind randomization study because it was the first study that 
had patients exercising while on ivabradine. Therefore, as a safety precaution, doctors were not 
blinded to who was receiving treatment.24 
 These studies also leave open many doors for an expanded off-label use of ivabradine. In 
the United Kingdom ivabradine is utilized for the treatment of inappropriate sinus tachycardia 
(IST).31-32 Future studies within the U.S. are warranted to determine if ivabradine is a viable and 
safe option for those with an IST diagnosis or other dysrhythmias by performing high quality 
random control trials. Also, there are currently 17 open clinical trials involving ivabradine, so it 
is expected that a plethora of data and evidence for off-label use will arise in the future.33      
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